Latest news

August 03, 2022 FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
July 29, 2022 AbbVie Reports Second-Quarter 2022 Financial Results
July 29, 2022 RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
寻找来自Abbvie的更多新闻？
Follow us onsocial media.

Quick links

Fact sheet

See a high-level overview about our business.

Image library

我们的媒体图书馆为您提供了我们的官方Abbvie媒体，包括我们的徽标，建筑和领导者。

Subscribe

Stay up to date on recent news, articles, and more.

Filter by categories




All news

September 23, 2013
Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases
August 19, 2013
Vote to Help Award a $21,000 AbbVie CF Scholarship to Two Inspirational Students with Cystic Fibrosis Pursuing their Goals of Higher Education
July 26, 2013
AbbVie Reports Second-Quarter 2013 Financial Results
July 08, 2013
Stacy London Launches Uncover Your Confidence™ Campaign to Empower People Living with Psoriasis
June 17, 2013
AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
June 13, 2013
AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis
June 05, 2013
AbbVie to Participate in 34th Annual Goldman Sachs Global Healthcare Conference
2013年6月3日
AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
May 30, 2013
AbbVie Announces Market Availability of New CREON® (pancrelipase) 36,000 Lipase-unit Capsules for Patients with Exocrine Pancreatic Insufficiency
May 28, 2013
AbbVie to Participate in 2013 Jeffries Global Healthcare Conference

More information

Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact.Learn more

Societal impact

Our commitment to science is a commitment to better our society.Read our 2021 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry.Learn more

Annual report

See our latest 2021 Annual Report on Form 10-K.Learn more

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, pleaseupdate your user profileand check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?